Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    25-May-2000      
Issue 42 Next Update - 14:00 UTC 08:00 EST    26-May-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Clamping Down On Medical Research

Clinton Administration Wants To Improve Patient Safety During Research Studies

The news has been filled with talk of improper, even fraudulent behavior during clinical trials. From improper report filing during Rezulin clinical trials to fraud during breast cancer chemotherapy trials, the clinical trial system appears to be in disarray. In response, the Clinton administration announced steps to improve patient safety during clinical trials.

New proposals from the administration address training issues, conflict of interest problems, additional powers for the FDA and observation of the informed consent process. More specifically the proposals seek to:

  • Require additional training of health professionals receiving grants from the National Institutes of Health.
  • Enhance the importance of the FDA in the clinical trials process by granting the organization the authoritiy to level fines of $250,000 per researcher or $1 million per institution for violations.
  • Researchers with a financial interest in the trial they are conducting will have to disclose that interest to potential patients.
  • The administration seeks to increase their observation of the informed consent process and seeks third-party presence during informed-consent meetings with trial participants.
  • Oversight of clinical trials will begin during smaller studies and earlier in the process.

The intended new policies are a repeat of the administration's call for better procedures. Industry leaders generally support the initiatives, though some feel the fines and penalties are in excess. The FDA already has the ability to stop research the agency feels is improper. Fines may only serve to scare some away from the clinical research process.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.